OncoMatch/Clinical Trials/NCT06313567
Metronomic Capecitabine in Stage III Gastric Cancer
Is NCT06313567 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Metronomic capecitabine group for gastric cancer.
Treatment: Metronomic capecitabine group — The purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage III who had received standard treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Gastric Cancer
Disease stage
Required: Stage III
Excluded: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
History of chemotherapy
Cannot have received: radiotherapy
History of radiotherapy
Cannot have received: immunotherapy
History of immunotherapy
Cannot have received: target therapy
History of target therapy
Lab requirements
Blood counts
WBC≥3.5 x 10^9 /L, NEU≥1.2 x 10^9 /L, PLT≥90 x 10^9 /L and HGB≥80g/L
Kidney function
normal kidney function
Liver function
normal liver function
Cardiac function
normal electrocardiogram
No contraindications, including normal peripheral blood routine, liver and kidney function and electrocardiogram （WBC≥3.5 x 109 /L, NEU≥1.2 x 109 /L,PLT≥90 x 109 /L and HGB≥80g/L)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06313567 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages